Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025 GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025. Participants can access the conference call live via , and also by visiting the page of Emergent’s website. To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive a confirmation email detailing how to j...
EQS-News: Northern Data AG / Key word(s): Agreement/Alliance Northern Data Group and Gcore announce strategic partnership to transform AI deployment and Inferencing 02.04.2025 / 08:25 CET/CEST The issuer is solely responsible for the content of this announcement. Northern Data Group and Gcore announce strategic partnership to transform AI deployment and Inferencing Partnership delivers full-stack AI platform – from foundational hardware to inference endpoints Proprietary Intelligence Delivery Network (IDN) creates low latency architecture that will unlock further acce...
EQS-News: Northern Data AG / Schlagwort(e): Vereinbarung/Kooperation Northern Data und Gcore kündigen strategische Kooperation an, um den Einsatz und das Inferencing von KI grundlegend zu transformieren 02.04.2025 / 08:25 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Northern Data und Gcore kündigen strategische Kooperation an, um den Einsatz und das Inferencing von KI grundlegend zu transformieren Die Kooperation liefert eine full-stack KI-Plattform - von der zu Grunde liegenden Hardware bis zum Inferencing Das proprietäre Inte...
In this quarterly strategy report, we look to evaluate where we are with regards the bull market conditions, and where those indicators might be headed, factoring in the downside risks, from Trump tariffs and the US economy, BoJ actions, Japanese earnings and valuations.
Emergent BioSolutions Announces Stock Repurchase Program GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company’s common stock on or before March 27, 2026. “As Emergent continues the turnaround phase of our multi-year transformation plan, we expect our investment priorities to remain focused on driving long-term growth and profitability,” said Joe Papa, president and CEO of Emergent. “This announcement reflects our confidence in the company’s...
EQS-News: Northern Data AG / Key word(s): Annual Report/Annual Results Northern Data Group releases audited FY 2024 Financial Results 28.03.2025 / 08:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE / IR NEWSNorthern Data Group releases audited FY 2024 Financial Results FY 2024 revenue of EUR 200 million, up 158% year-on-year, in line with preliminary figures published on 21 January 2025 Cloud and data center FY 2024 revenue of EUR 121 million, up 722% year-on-year, also in line with preliminary figures Adjusted EBITDA1...
EQS-News: Northern Data AG / Schlagwort(e): Jahresbericht/Jahresergebnis Northern Data Group veröffentlicht die geprüften Finanzergebnisse für das Geschäftsjahr 2024 28.03.2025 / 08:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PRESSEINFORMATION/ IR-NACHRICHTNorthern Data Group veröffentlicht die geprüften Finanzergebnisse für das Geschäftsjahr 2024 Umsatz im Geschäftsjahr 2024: EUR 200 Mio., ein Anstieg von 158 % im Jahresvergleich, im Einklang mit den am 21. Januar 2025 veröffentlichten vorläufigen Zahlen Umsatz im Bereich ...
Three Directors at Royal Bank Of Canada sold/sold after exercising options 21,013 shares at 161.890CAD. The significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the "Inducement Plan"). The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the “Equity Award”) as of M...
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada LONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system de...
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International. Emergent received approximately $36.5 million at closing, which is subject to customary post-closing adjustments. Pursuant to the sale, Syngene acquired the assets and equipment associated with the Baltimore-Bayview facility. In addition, Emergent retains the righ...
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products GAITHERSBURG, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has recently secured approximately $27 million in international orders targeted for delivery in 2025 associated with its medical countermeasures (MCM) portfolio. These orders will help address potential threats of smallpox and anthrax and will contribute to the overall supply of MCM’s to the international market in 20...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.